Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK101 in Moderate-to-Severe Plaque Psoriasis (China, Phase II)
CTR20201440Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ebdarokimab in plaque psoriasis, sponsored by Akeso, Inc.. Started Aug 2020; status: completed.
02
Drugs
ebdarokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20201440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201440.